Erythropoietin in cardioprotection: does it have a future or is it all in the past?
Mehta
Jawahar L
JL
D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004304:Dosage Forms; D004337:Drug Carriers; D004921:Erythropoietin / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007279:Injections, Subcutaneous; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology / Q000473:pathology; D011994:Recombinant Proteins; D015398:Signal Transduction / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects; D020257:Ventricular Remodeling / Q000187:drug effects
D002317:Cardiovascular Agents; D004304:Dosage Forms; D004337:Drug Carriers; D011994:Recombinant Proteins; D004921:Erythropoietin